Airsculpt Technologies, Inc.
Business
AirSculpt Technologies, Inc. is a provider of minimally invasive body contouring procedures using a proprietary, patented AirSculpt® method that removes fat and tightens skin without needle, scalpel, stitches or general anesthesia. The company offers a broad suite of fat removal and fat transfer procedures, including branded treatments such as Power BBL®, Up a Cup™, and Hip Flip™, as well as innovative skin-tightening and cellulite-reduction services. AirSculpt operates a network of 31 physician-affiliated centers across 20 U.S. states and Canada, structured as professional medical associations with affiliated management service agreements, serving affluent metropolitan and suburban markets through an all-private-pay model.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 152 | 180 | 196 | 169 | 133 | |
| Cost of service (exclusive of depreciation and amortization) | 62 | 71 | 74 | 63 | 45 | |
| Selling, general and administrative | 82 | 99 | 102 | 101 | 66 | |
| Depreciation and amortization | 13 | 12 | 10 | 8 | 7 | |
| Loss/(gain) on disposal of long-lived assets | 5 | 16,000 | −212,000 | 147,000 | 0 | |
| Loss/(gain) on disposal of long-lived assets | 2 | 0 | 0 | — | — | |
| Total operating expenses | 163 | 182 | 186 | 173 | 118 | |
| (Loss)/income from operations | −12 | −2 | 10 | −5 | 16 | |
| Interest expense, net | 6 | 6 | 6 | 7 | — | |
| Pre-tax net loss | −18 | −8 | 3 | −11 | 11 | |
| Total | −6 | 188,000 | 7 | 3 | 329,000 | |
| Net loss | −12 | −8 | −4 | −15 | 11 | |
| Basic (in dollars per share) | −0.19 | −0.14 | −0.08 | −0.26 | −0.01 | |
| Diluted (in dollars per share) | −0.19 | −0.14 | −0.08 | −0.26 | −0.01 | |
| Basic (in shares) | 60 | 58 | 57 | 56 | 56 | |
| Diluted (in shares) | 60 | 58 | 57 | 56 | 56 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 8 | 10 | 10 | 25 | |
| Taxes receivable | 1 | 3 | 2 | 3 | 0 | |
| Prepaid expenses and other current assets | 6 | 6 | 4 | 4 | 4 | |
| Total current assets | 15 | 17 | 16 | 17 | 29 | |
| Property and equipment, net | 28 | 37 | 29 | 24 | 14 | |
| Other long-term assets | 3 | 5 | 6 | 3 | 2 | |
| Right of use operating lease assets | 22 | 29 | 25 | 24 | 18 | |
| Intangible assets, net | 37 | 42 | 46 | 51 | 56 | |
| Goodwill | 82 | 82 | 82 | 82 | 82 | |
| Total assets | 187 | 213 | 204 | 201 | 201 | |
| Accounts payable | 5 | 6 | 4 | 4 | 3 | |
| Accrued payroll and benefits | 3 | 3 | 4 | 3 | 3 | |
| Current portion of long-term debt | 5 | 4 | 2 | 2 | 850,000 | |
| Deferred revenue and patient deposits | 2 | 1 | 1 | 2 | 3 | |
| Accrued and other current liabilities | 5 | 8 | 3 | 7 | 4 | |
| Current operating lease liabilities | 7 | 6 | 5 | 4 | 3 | |
| Total current liabilities | 28 | 29 | 20 | 22 | 16 | |
| Long-term debt, net | 51 | 65 | 70 | 81 | 82 | |
| Deferred tax liability, net | 878,000 | 7 | 7 | 5 | 4 | |
| Long-term operating lease liabilities | 20 | 28 | 23 | 20 | 15 | |
| Revolving credit funds payable | 0 | 5 | 0 | — | — | |
| Other long-term liabilities | 0 | 817,000 | 716,000 | 1 | 0 | |
| Total liabilities | 100 | 135 | 120 | 130 | 117 | |
| Commitments and contingent liabilities (Note 9) | — | — | — | — | — | |
| Common stock, $0.001 par value; shares authorized - 450,000,000; shares issued and outstanding - 64,455,872 and 58,369,138, respectively | 64,000 | 58,000 | 57,000 | 56,000 | 56,000 | |
| Additional paid-in capital | 128 | 108 | 104 | 86 | 84 | |
| Accumulated other comprehensive loss | −96,000 | −687,000 | −412,000 | −76,000 | 0 | |
| Accumulated deficit | −41 | −29 | −20 | −15 | −393,000 | |
| Total stockholders' equity | 88 | 78 | 83 | 71 | 84 | |
| Total liabilities and stockholders' equity | 187 | 213 | 204 | 201 | 201 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Equity-based compensation | 2 | 4 | 18 | 29 | 7 | |
| Non-cash interest expense; amortization of debt costs | 500,000 | 300,000 | 200,000 | 900,000 | 600,000 | |
| Deferred income taxes | −6 | −252,000 | 1 | 1 | 208,000 | |
| Cost related to closing location | 2 | 0 | 0 | — | — | |
| Taxes receivable | 2 | −1 | 890,000 | −3 | 0 | |
| Prepaid expense and other current assets | −4 | −2 | 466,000 | −5,000 | −4 | |
| Other assets | 7 | −3 | −5 | −7 | −1 | |
| Accounts payable | 579,000 | 739,000 | −206,000 | 865,000 | 2 | |
| Deferred revenue and patient deposits | 735,000 | −293,000 | −896,000 | −452,000 | −423,000 | |
| Accrued and other liabilities | −7 | 9 | 3 | 8 | 5 | |
| Net cash used in operating activities | 3 | 11 | 24 | 24 | 27 | |
| Purchases of property and equipment, net | −2 | −14 | −10 | −13 | −7 | |
| Net cash used in investing activities | −2 | −14 | −10 | −13 | −7 | |
| Payments on term loan | −14 | −2 | −12 | −84 | −838,000 | |
| Payments for debt modification | −393,000 | −136,000 | 0 | 0 | — | |
| Payments on revolving credit facility | −5 | 5 | 0 | — | — | |
| Proceeds from public offerings, net | 19 | 0 | 0 | — | — | |
| Distribution to member | 0 | 0 | −79,000 | −1 | −67 | |
| Dividends paid to shareholders | 0 | −252,000 | −385,000 | −23 | 0 | |
| Payment of taxes withheld through vested equity-based compensation | −56,000 | −903,000 | −233,000 | −2 | 0 | |
| Other financing activity | 0 | −954,000 | −569,000 | −147,000 | 0 | |
| Net cash used in financing activities | −478,000 | 630,000 | −13 | −27 | −5 | |
| Net decrease in cash and cash equivalents | 214,000 | −2 | 646,000 | −16 | 15 | |
| Cash paid for interest | 6 | 6 | 6 | 6 | 4 | |
| Property and equipment included in accounts payable and accrued expenses | 2 | 2 | 283,000 | 1 | 255,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Airsculpt Technologies, Inc.'s CIK number?
Airsculpt Technologies, Inc.'s SEC CIK number is 0001870940 (1870940). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Airsculpt Technologies, Inc.'s SEC filings?
All of Airsculpt Technologies, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Airsculpt Technologies, Inc. last report earnings?
Airsculpt Technologies, Inc. (AIRS) most recently filed an earnings 8-K with the SEC on May 8, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001870940-26-000026). This is Airsculpt Technologies, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Airsculpt Technologies, Inc.'s most recent earnings 8-K?
Airsculpt Technologies, Inc.'s latest earnings 8-K (Item 2.02) was filed May 8, 2026 under accession 0001870940-26-000026. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Airsculpt Technologies, Inc.'s latest earnings 8-K →
Look up any company's CIK number →